13 September 2022 | News
Features enhanced technology that builds on company’s decades of expertise in the prefillable syringe market
BD (Becton, Dickinson and Company) has introduced a next-generation glass prefillable syringe (PFS) that sets a new standard in performance for vaccine PFS with new and tightened specifications for processability, cosmetics, contamination and integrity.
The new BD Effivax Glass Prefillable Syringe has been designed in collaboration with leading pharmaceutical companies to meet the complex and evolving needs of vaccine manufacturing.
Approximately 70 percent of the top 100 biopharmaceutical companies rely on BD for supply of PFS.2 BD Effivax Glass Prefillable Syringe will further help customers meet the stringent demands of today’s vaccine manufacturing through design enhancements focused on fill/finish and container reliability. Through improved quality specifications, BD BD Effivax is designed to reduce the risk of line stoppage3 and improve the total cost of ownership,4 manufacturing capacity and supply availability.
The BD Effivax Glass Prefillable Syringe will benefit from the $1.2 billion, four-year investment that BD announced in late 2020 to expand and upgrade manufacturing capacity and technology for PFS.